Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Clinical Trial ID NCT01472081

PubWeight™ 51.61‹?›

🔗 Visit the page for NCT01472081

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
4 Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015 2.30
5 The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) 2015 2.17
6 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
7 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
8 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
9 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
10 Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013 1.39
11 Control of the immune response by pro-angiogenic factors. Front Oncol 2014 1.26
12 CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2015 1.15
13 Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2013 0.98
14 First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 2014 0.95
15 Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev 2016 0.90
16 Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 2014 0.89
17 Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016 0.89
18 Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015 0.88
19 Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol 2016 0.86
20 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
21 PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014 0.85
22 Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 2016 0.84
23 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
24 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
25 The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol 2013 0.81
26 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
27 Therapeutic challenges in renal cell carcinoma. Am J Clin Exp Urol 2015 0.80
28 Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer 2014 0.80
29 Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015 0.79
30 Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol 2015 0.78
31 Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 2016 0.78
32 Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015 0.77
33 Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2016 0.77
34 Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open 2016 0.77
35 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
36 An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res 2015 0.76
37 Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol 2013 0.75
38 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
39 Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016 0.75
40 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
41 A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position. Clin Genitourin Cancer 2012 0.75
Next 100